July 10, 2024 Sophia Vida
Breaking News

BioStem Receives Institutional Review Board (IRB) Approval to Advance a Clinical Study Evaluating AmnioWrap2™ in Diabetic Foot Ulcers

POMPANO BEACH, FL, July 10, 2024 – BioStem Technologies Inc. (OTC: BSEM), a leading regenerative medicine company focused on the development, manufacture, and commercialization of placental-derived biologics for advanced wound care, announces that the IRB has approved a clinical study to evaluate AmnioWrap2™ (AW2) in diabetic foot ulcers (DFU), one of the company’s placental-derived allograft … Continue reading “BioStem Receives Institutional Review Board (IRB) Approval to Advance a Clinical Study Evaluating AmnioWrap2™ in Diabetic Foot Ulcers”